Anthony J Cleare1, Cristina Messa, Eugenii A Rabiner, Paul M Grasby. 1. Section of Neurobiology of Mood Disorders, Division of Psychological Medicine, Institute of Psychiatry and Guy-s, King-s and St. Thomas- School of Medicine, London, United Kingdom. a.cleare@iop.kcl.ac.uk
Abstract
BACKGROUND: Research from neuroendocrine challenge and other indirect studies has suggested increased central 5-HT function in chronic fatigue syndrome (CFS) and increased 5-HT1A receptor sensitivity. We assessed brain 5-HT1A receptor binding potential directly using the specific radioligand [11C]WAY-100635 and positron emission tomography (PET). METHODS: We selected 10 patients from a tertiary referral clinic who fulfilled the CDC consensus criteria for CFS. To assemble a homogenous group and avoid confounding effects, we enrolled only subjects who were completely medication-free and did not have current comorbid psychiatric illness. We also scanned 10 healthy control subjects. RESULTS: There was a widespread reduction in 5-HT1A receptor binding potential in CFS relative to control subjects. This was particularly marked in the hippocampus bilaterally, where a 23% reduction was observed. CONCLUSIONS: There is evidence of decreased 5-HT1A receptor number or affinity in CFS. This may be a primary feature of CFS, related to the underlying pathophysiology, or a finding secondary to other processes, such as previous depression, other biological changes or the behavioral consequences of CFS.
BACKGROUND: Research from neuroendocrine challenge and other indirect studies has suggested increased central 5-HT function in chronic fatigue syndrome (CFS) and increased 5-HT1A receptor sensitivity. We assessed brain 5-HT1A receptor binding potential directly using the specific radioligand [11C]WAY-100635 and positron emission tomography (PET). METHODS: We selected 10 patients from a tertiary referral clinic who fulfilled the CDC consensus criteria for CFS. To assemble a homogenous group and avoid confounding effects, we enrolled only subjects who were completely medication-free and did not have current comorbid psychiatric illness. We also scanned 10 healthy control subjects. RESULTS: There was a widespread reduction in 5-HT1A receptor binding potential in CFS relative to control subjects. This was particularly marked in the hippocampus bilaterally, where a 23% reduction was observed. CONCLUSIONS: There is evidence of decreased 5-HT1A receptor number or affinity in CFS. This may be a primary feature of CFS, related to the underlying pathophysiology, or a finding secondary to other processes, such as previous depression, other biological changes or the behavioral consequences of CFS.
Authors: Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King Journal: Neuropsychol Rev Date: 2005-03 Impact factor: 7.444
Authors: Shelley A Weaver; Malvin N Janal; Nadine Aktan; John E Ottenweller; Benjamin H Natelson Journal: J Womens Health (Larchmt) Date: 2010-05 Impact factor: 2.681
Authors: David Benjamin Fischer; Arsani Hany William; Adam Campbell Strauss; Elizabeth R Unger; Leonard Jason; Gailen D Marshall; Jordan D Dimitrakoff Journal: Fatigue Date: 2014-06-01
Authors: Wayne C Drevets; Michael E Thase; Eydie L Moses-Kolko; Julie Price; Ellen Frank; David J Kupfer; Chester Mathis Journal: Nucl Med Biol Date: 2007-10 Impact factor: 2.408